Monaco Asset Management SAM Invests $338,000 in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Key Points

• Monaco Asset Management SAM has taken a new stake in Lexicon Pharmaceuticals, purchasing 734,148 shares valued at approximately $338,000, representing about 0.20% ownership of the company.
• Investment firms such as Point72 Asset Management and Schoenfeld Strategic Advisors increased their stakes significantly, with Point72 growing its ownership by 630.7% to hold nearly 9 million shares.
• Analysts have mixed ratings on Lexicon Pharmaceuticals, with a consensus target price of $3.67 and ratings varying from "sell" to "buy," indicating uncertainty in the stock's future performance.

Monaco Asset Management SAM purchased a new position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 734,148 shares of the biopharmaceutical company's stock, valued at approximately $338,000. Monaco Asset Management SAM owned about 0.20% of Lexicon Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in LXRX. Teacher Retirement System of Texas grew its holdings in Lexicon Pharmaceuticals by 60.3% during the 4th quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company's stock worth $48,000 after acquiring an additional 24,615 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $66,000. Wellington Management Group LLP boosted its holdings in shares of Lexicon Pharmaceuticals by 2.1% in the 4th quarter. Wellington Management Group LLP now owns 747,996 shares of the biopharmaceutical company's stock valued at $552,000 after buying an additional 15,249 shares in the last quarter. RPO LLC bought a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $33,000. Finally, Cerity Partners LLC boosted its holdings in shares of Lexicon Pharmaceuticals by 328.7% in the 4th quarter. Cerity Partners LLC now owns 96,512 shares of the biopharmaceutical company's stock valued at $71,000 after buying an additional 74,000 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Price Performance

Shares of Lexicon Pharmaceuticals stock remained flat at $1.07 during midday trading on Friday. 1,138,739 shares of the company traded hands, compared to its average volume of 3,428,581. The stock has a market capitalization of $386.79 million, a PE ratio of -2.10 and a beta of 1.17. The company has a current ratio of 2.22, a quick ratio of 2.22 and a debt-to-equity ratio of 0.48. The business has a 50-day moving average price of $0.90 and a two-hundred day moving average price of $0.70. Lexicon Pharmaceuticals, Inc. has a 52-week low of $0.28 and a 52-week high of $2.18.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 568.04% and a negative return on equity of 103.16%. The firm had revenue of $1.26 million during the quarter, compared to analyst estimates of $1.26 million. As a group, analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on LXRX. HC Wainwright restated a "buy" rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a report on Tuesday, June 24th. Wall Street Zen began coverage on shares of Lexicon Pharmaceuticals in a report on Monday, April 21st. They issued a "sell" rating on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $3.67.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.